Skip to main content
Top
Published in: Clinical Reviews in Bone and Mineral Metabolism 3-4/2011

01-12-2011 | Original Paper

Miscellaneous Stone Types

Authors: James B. Cutrell, Robert F. Reilly

Published in: Clinical & Translational Metabolism | Issue 3-4/2011

Login to get access

Abstract

Drug-induced calculi and other rare stone types, such as ammonium acid urate or protein matrix stones, represent only about 2% of all renal calculi. However, the chance to easily reverse stone formation risk by discontinuing the offending drug makes identification of these entities important for clinicians. Additionally, study of these rare stone types contributes to understanding the biochemistry of stone formation. Drug-induced calculi may be classified into two groups based on the mechanism of stone formation. The first group includes drugs that provoke calculi composed of principally the drug and its metabolites. These medications tend to be poorly soluble, highly excreted in urine, and required at high dosages for long durations of therapy. Historically, sulfonamides, triamterene, and the HIV protease inhibitor indinavir were leading causes of drug-induced calculi. Uses of novel agents within these drug classes or alternative therapies have reduced the incidence attributed to these drugs, although risk from newer, commonly used medications–notably ciprofloxacin, aminopenicillins, ceftriaxone, ephedrine, and guaifenesin– are increasingly being recognized. Microscopic analysis for crystalluria or infrared spectroscopy of collected stones aid in recognition of calculi composed primarily of a drug and its metabolites. Understanding of drug metabolism and pharmacokinetics, particularly related to effects of urine pH on drug solubility and excretion, provides a rational basis for both prevention and treatment recommendations. When possible, clinicians should avoid or exercise great caution when prescribing these medications to patients with a prior history of stones. The second group of drug-induced calculi includes drugs that cause stones due to their metabolic effects, primarily on calcium or purine metabolism. Because these calculi are identical in physical composition to the more common nephrolithiasis types, careful medication history and high clinical suspicion are required for diagnosis of these drug-induced “metabolic” calculi. Most drugs in this class are readily expected based on their effects on urinary calcium excretion such as calcium/Vitamin D supplements and loop diuretics. Carbonic anhydrase inhibitors, including the antiepileptics topiramate and zonisamide, are also included in this group. Ammonium acid urate stones are endemic in developing countries due to dietary limitations and recurrent diarrheal illness, but rarely occur in developed countries. Identification of these stones should raise clinical suspicion of epidemiologic risk factors including recurrent urinary tract infections with urea-splitting organisms, inflammatory bowel disease, and laxative abuse. Interestingly, these unusual clinical scenarios can recapitulate a common biochemical pathway to stone formation. Protein matrix stones are another unusual stone type associated with specific epidemiologic factors, namely recurrent urinary infections and proteinuric end-stage renal disease. Although distinctly rare, protein matrix stones provide opportunity to investigate basic biochemical mechanisms underlying stone formation.
Literature
1.
go back to reference Antopol W, Robinson H. Urolithiasis and renal pathology after administration of sulfapyridine. Proc Soc Exp Biol Med. 1939;40:428–39. Antopol W, Robinson H. Urolithiasis and renal pathology after administration of sulfapyridine. Proc Soc Exp Biol Med. 1939;40:428–39.
2.
go back to reference Lehr D, Antopol W, Churg J. Massive “acute” precipitation of free sulfathiazole in the urinary tract. Science. 1940;92(2393):434–5.PubMedCrossRef Lehr D, Antopol W, Churg J. Massive “acute” precipitation of free sulfathiazole in the urinary tract. Science. 1940;92(2393):434–5.PubMedCrossRef
3.
go back to reference Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention, and management. Drugs. 2004;64(3):245–75.PubMedCrossRef Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention, and management. Drugs. 2004;64(3):245–75.PubMedCrossRef
4.
go back to reference Matlaga BR, Shah OD, Assimos DG. Drug-induced urinary calculi. Rev Urol. 2003;5(4):227–31.PubMed Matlaga BR, Shah OD, Assimos DG. Drug-induced urinary calculi. Rev Urol. 2003;5(4):227–31.PubMed
6.
go back to reference Daudon M, Bader CA, Jungers P. Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc. 1993;7(3):1081–104.PubMed Daudon M, Bader CA, Jungers P. Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc. 1993;7(3):1081–104.PubMed
7.
8.
go back to reference Rapado A, Traba ML, Caycho C, Cifuentes-Delatte L. Drug-induced renal stones: incidence, clinical expression, and stone analysis. Contrib Nephrol. 1987;58:25–9.PubMed Rapado A, Traba ML, Caycho C, Cifuentes-Delatte L. Drug-induced renal stones: incidence, clinical expression, and stone analysis. Contrib Nephrol. 1987;58:25–9.PubMed
9.
go back to reference Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited: The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150(11):2379–84.PubMedCrossRef Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited: The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150(11):2379–84.PubMedCrossRef
10.
go back to reference Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis. 1988;12(1):72–5.PubMed Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis. 1988;12(1):72–5.PubMed
11.
go back to reference Díaz F, Collazos J, Mayo J, Martínez E. Sulfadiazine-induced multiple urolithiasis, acute renal failure in a patient with AIDS, Toxoplasma encephalitis. Ann Pharmacother. 1996;30(1):41–2.PubMed Díaz F, Collazos J, Mayo J, Martínez E. Sulfadiazine-induced multiple urolithiasis, acute renal failure in a patient with AIDS, Toxoplasma encephalitis. Ann Pharmacother. 1996;30(1):41–2.PubMed
12.
go back to reference Catalano-Pons C, Bargy S, Schlecht D, Tabone MD, Deschenes G, Bensman A, et al. Sulfadiazine-induced nephrolithiasis in children. Pediatr Nephrol. 2004;19(8):928–31.PubMedCrossRef Catalano-Pons C, Bargy S, Schlecht D, Tabone MD, Deschenes G, Bensman A, et al. Sulfadiazine-induced nephrolithiasis in children. Pediatr Nephrol. 2004;19(8):928–31.PubMedCrossRef
13.
go back to reference Molina JM, Belenfant X, Doco-Lecompte T, Idatte JM, Modai J. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS. 1991;5(5):587–9.PubMedCrossRef Molina JM, Belenfant X, Doco-Lecompte T, Idatte JM, Modai J. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS. 1991;5(5):587–9.PubMedCrossRef
14.
go back to reference Becker K, Jablonowski H, Häussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine. 1996;75(4):185–94.PubMedCrossRef Becker K, Jablonowski H, Häussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine. 1996;75(4):185–94.PubMedCrossRef
15.
go back to reference Crespo M, Quereda C, Pascual J, Rivera M, Clemente L, Cano T. Patterns of sulfadiazine acute nephrotoxicity. Clin Nephrol. 2000;54(1):68–72.PubMed Crespo M, Quereda C, Pascual J, Rivera M, Clemente L, Cano T. Patterns of sulfadiazine acute nephrotoxicity. Clin Nephrol. 2000;54(1):68–72.PubMed
16.
go back to reference Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C. Acute renal failure due to sulfadiazine in patients with AIDS. Nephron. 1990;55(2):233–4.PubMedCrossRef Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C. Acute renal failure due to sulfadiazine in patients with AIDS. Nephron. 1990;55(2):233–4.PubMedCrossRef
17.
go back to reference Dusseault BN, Croce KJ, Pais VM Jr. Radiographic characteristics of sulfadiazine urolithiasis. Urology. 2009;73(4):928.e5–6.CrossRef Dusseault BN, Croce KJ, Pais VM Jr. Radiographic characteristics of sulfadiazine urolithiasis. Urology. 2009;73(4):928.e5–6.CrossRef
18.
go back to reference Perazella MA. Drug-induced renal failure: update on new medications, unique mechanisms of nephrotoxicity. Am J Med Sci. 2003;325(6):349–62.PubMedCrossRef Perazella MA. Drug-induced renal failure: update on new medications, unique mechanisms of nephrotoxicity. Am J Med Sci. 2003;325(6):349–62.PubMedCrossRef
19.
go back to reference Buchanan N. Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure. Br Med J. 1978;2(6131):172.PubMedCrossRef Buchanan N. Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure. Br Med J. 1978;2(6131):172.PubMedCrossRef
20.
go back to reference Siegel WH. Unusual complication of therapy with sulfamethoxazole-trimethoprim. J Urol. 1977;117(3):397.PubMed Siegel WH. Unusual complication of therapy with sulfamethoxazole-trimethoprim. J Urol. 1977;117(3):397.PubMed
21.
go back to reference Albala DM, Prien EL Jr, Galal HA. Urolithiasis as a hazard of sulfonamide therapy. J Endourol. 1994;8(6):401–3.PubMedCrossRef Albala DM, Prien EL Jr, Galal HA. Urolithiasis as a hazard of sulfonamide therapy. J Endourol. 1994;8(6):401–3.PubMedCrossRef
22.
go back to reference Sillar DB, Kleinig D. Sulphur calculi from ingestion of sulphasalazine. Br J Urol. 1993;71(6):750–1.PubMedCrossRef Sillar DB, Kleinig D. Sulphur calculi from ingestion of sulphasalazine. Br J Urol. 1993;71(6):750–1.PubMedCrossRef
23.
go back to reference Erturk E, Casemento JB, Guertin KR, Kende AS. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol. 1994;151(6):1605–6.PubMed Erturk E, Casemento JB, Guertin KR, Kende AS. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol. 1994;151(6):1605–6.PubMed
24.
go back to reference Russinko PJ, Agarwal S, Choi MJ, Kelty PJ. Obstructive nephropathy secondary to sulfasalazine calculi. Urology. 2003;62(4):748.PubMedCrossRef Russinko PJ, Agarwal S, Choi MJ, Kelty PJ. Obstructive nephropathy secondary to sulfasalazine calculi. Urology. 2003;62(4):748.PubMedCrossRef
25.
go back to reference Ettinger B, Weil E, Mandel NS, Darling S. Triamterene-induced nephrolithiasis. Ann Intern Med. 1979;91(5):745–6.PubMed Ettinger B, Weil E, Mandel NS, Darling S. Triamterene-induced nephrolithiasis. Ann Intern Med. 1979;91(5):745–6.PubMed
26.
27.
go back to reference White DJ, Nancollas GH. Triamterene and renal stone formation. J Urol. 1982;127(3):593–7.PubMed White DJ, Nancollas GH. Triamterene and renal stone formation. J Urol. 1982;127(3):593–7.PubMed
29.
go back to reference Sörgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol. 1985;134(5):871–3.PubMed Sörgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol. 1985;134(5):871–3.PubMed
30.
go back to reference Fairley KF, Birch DF, Haines I. Abnormal urinary sediment in patients on triamterene. Lancet. 1983;1(8321):421–2.PubMedCrossRef Fairley KF, Birch DF, Haines I. Abnormal urinary sediment in patients on triamterene. Lancet. 1983;1(8321):421–2.PubMedCrossRef
31.
go back to reference Carey RA, Beg MM, McNally CF, Tannenbaum P. Triamterene and renal lithiasis: a review. Clin Ther. 1984;6(3):302–9.PubMed Carey RA, Beg MM, McNally CF, Tannenbaum P. Triamterene and renal lithiasis: a review. Clin Ther. 1984;6(3):302–9.PubMed
32.
go back to reference Ettinger B. Excretion of triamterene, its metabolite in triamterene stone patients. J Clin Pharmacol. 1985;25(5):365–8.PubMed Ettinger B. Excretion of triamterene, its metabolite in triamterene stone patients. J Clin Pharmacol. 1985;25(5):365–8.PubMed
33.
go back to reference Kau ST. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther. 1978;206(3):701–9.PubMed Kau ST. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther. 1978;206(3):701–9.PubMed
34.
go back to reference Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet. 1985;2(8446):73–5.PubMedCrossRef Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet. 1985;2(8446):73–5.PubMedCrossRef
35.
go back to reference Merck & Co. Crixivan (indinavir sulfate)–U.S. package insert. PA: West Point; 1996. Merck & Co. Crixivan (indinavir sulfate)–U.S. package insert. PA: West Point; 1996.
36.
go back to reference Daudon M, Estépa L, Viard JP, Joly D, Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997;349(9061):1294–5.PubMedCrossRef Daudon M, Estépa L, Viard JP, Joly D, Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997;349(9061):1294–5.PubMedCrossRef
37.
go back to reference Kopp JB, Miller KD, Mican JA, Feuersterin IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119–25.PubMed Kopp JB, Miller KD, Mican JA, Feuersterin IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119–25.PubMed
38.
go back to reference Reiter WJ, Schön-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol. 1999;161(4):1082–4.PubMedCrossRef Reiter WJ, Schön-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol. 1999;161(4):1082–4.PubMedCrossRef
39.
go back to reference Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133(1):35–9.PubMed Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133(1):35–9.PubMed
40.
go back to reference Saltel E, Angel JB, Futter NG, Walsh WG, O’Rourke K, Mahoney JE. Increased prevalence, analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164(6):1895–7.PubMedCrossRef Saltel E, Angel JB, Futter NG, Walsh WG, O’Rourke K, Mahoney JE. Increased prevalence, analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164(6):1895–7.PubMedCrossRef
41.
42.
go back to reference Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol. 1998;50(3):194–6.PubMed Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol. 1998;50(3):194–6.PubMed
43.
go back to reference Famularo G, Di Toro S, Moretti S, De Simone C. Symptomatic crystalluria associated with indinavir. Ann Pharmacother. 2000;34(12):1414–8.PubMedCrossRef Famularo G, Di Toro S, Moretti S, De Simone C. Symptomatic crystalluria associated with indinavir. Ann Pharmacother. 2000;34(12):1414–8.PubMedCrossRef
44.
go back to reference Gagnon RF, Tecimer SN, Watters AK, Tsoukas CM. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis. 2000;36(3):507–15.PubMedCrossRef Gagnon RF, Tecimer SN, Watters AK, Tsoukas CM. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis. 2000;36(3):507–15.PubMedCrossRef
45.
go back to reference Marroni M, Gaburri M, Mecozzi F, Baldelli F. Acute interstitial nephritis secondary to administration of indinavir. Ann Pharmacother. 1998;32(7–8):843–4.PubMed Marroni M, Gaburri M, Mecozzi F, Baldelli F. Acute interstitial nephritis secondary to administration of indinavir. Ann Pharmacother. 1998;32(7–8):843–4.PubMed
46.
go back to reference Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563–73.PubMedCrossRef Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563–73.PubMedCrossRef
47.
go back to reference Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis. 2001;38(4):E23.PubMedCrossRef Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis. 2001;38(4):E23.PubMedCrossRef
48.
go back to reference Meraviglia P, Angeli E, Del Sorbo F, Rombolà G, Viganò P, Orlando G, et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS. 2002;16(15):2089–93.PubMedCrossRef Meraviglia P, Angeli E, Del Sorbo F, Rombolà G, Viganò P, Orlando G, et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS. 2002;16(15):2089–93.PubMedCrossRef
49.
go back to reference Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS. 1998;12(18):2433–7.PubMedCrossRef Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS. 1998;12(18):2433–7.PubMedCrossRef
50.
go back to reference Malavaud B, Dinh B, Bonnet E, Izopet J, Payen JL, Marchou B. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther. 2000;5(1):3–5.PubMed Malavaud B, Dinh B, Bonnet E, Izopet J, Payen JL, Marchou B. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther. 2000;5(1):3–5.PubMed
52.
go back to reference Pacanowski J, Poirier JM, Petit I, Meynard JL, Girard PM. Atazanavir urinary stones in an HIV-infected patient. AIDS. 2006;20(16):2131.PubMedCrossRef Pacanowski J, Poirier JM, Petit I, Meynard JL, Girard PM. Atazanavir urinary stones in an HIV-infected patient. AIDS. 2006;20(16):2131.PubMedCrossRef
53.
go back to reference Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS. 2007;21(9):1215–8.PubMedCrossRef Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS. 2007;21(9):1215–8.PubMedCrossRef
54.
go back to reference Green ST, McKendrick MW, Schmid ML, Mohsen AH, Prakasam SP. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9(9):555.PubMedCrossRef Green ST, McKendrick MW, Schmid ML, Mohsen AH, Prakasam SP. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9(9):555.PubMedCrossRef
55.
go back to reference Engeler DS, John H, Rentsch KM, Ruef C, Oertle D, Suter S. Nelfinavir urinary stones. J Urol. 2002;167(3):1384–5.PubMedCrossRef Engeler DS, John H, Rentsch KM, Ruef C, Oertle D, Suter S. Nelfinavir urinary stones. J Urol. 2002;167(3):1384–5.PubMedCrossRef
56.
go back to reference Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18(4):705–6.PubMedCrossRef Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18(4):705–6.PubMedCrossRef
57.
go back to reference Izzedine H, Valantin MA, Daudon M, Mohand HA, Caby F, Katlama C. Efavirenz urolithiasis. AIDS. 2007;21(14):1992.PubMedCrossRef Izzedine H, Valantin MA, Daudon M, Mohand HA, Caby F, Katlama C. Efavirenz urolithiasis. AIDS. 2007;21(14):1992.PubMedCrossRef
58.
go back to reference Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith ND. The etiology of urolithiasis in HIV infected patients. J Urol. 2003;169(2):475–7.PubMedCrossRef Nadler RB, Rubenstein JN, Eggener SE, Loor MM, Smith ND. The etiology of urolithiasis in HIV infected patients. J Urol. 2003;169(2):475–7.PubMedCrossRef
59.
go back to reference Chopra N, Fine PL, Price B, Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria, stone formation. J Urol. 2000;164(2):438.PubMedCrossRef Chopra N, Fine PL, Price B, Atlas I. Bilateral hydronephrosis from ciprofloxacin induced crystalluria, stone formation. J Urol. 2000;164(2):438.PubMedCrossRef
60.
go back to reference Labriola L, Jadoul M, Daudon M, Pirson Y, Lambert M. Massive amoxicillin crystalluria causing anuric acute renal failure. Clin Nephrol. 2003;59(6):455–7.PubMed Labriola L, Jadoul M, Daudon M, Pirson Y, Lambert M. Massive amoxicillin crystalluria causing anuric acute renal failure. Clin Nephrol. 2003;59(6):455–7.PubMed
61.
go back to reference Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2(8625):1411–3.PubMedCrossRef Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet. 1988;2(8625):1411–3.PubMedCrossRef
62.
go back to reference Cochat P, Cochat N, Jouvenet M, Floret D, Wright C, Martin X, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant. 1990;5(11):974–6.PubMed Cochat P, Cochat N, Jouvenet M, Floret D, Wright C, Martin X, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant. 1990;5(11):974–6.PubMed
63.
go back to reference Avci Z, Koktener A, Uras N, Catal F, Karadag A, Tekin O, et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child. 2004;89(11):1069–72.PubMedCrossRef Avci Z, Koktener A, Uras N, Catal F, Karadag A, Tekin O, et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child. 2004;89(11):1069–72.PubMedCrossRef
64.
go back to reference Mohkam M, Karimi A, Gharib A, Daneshmand H, Khatami A, Ghoievand N, et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol. 2007;22(5):690–4.PubMedCrossRef Mohkam M, Karimi A, Gharib A, Daneshmand H, Khatami A, Ghoievand N, et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol. 2007;22(5):690–4.PubMedCrossRef
65.
go back to reference Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med. 1975;292(12):626–7.PubMedCrossRef Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med. 1975;292(12):626–7.PubMedCrossRef
66.
go back to reference Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med. 1969;280(8):426–7.PubMedCrossRef Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med. 1969;280(8):426–7.PubMedCrossRef
67.
go back to reference Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol. 1983;130(1):157–9.PubMed Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol. 1983;130(1):157–9.PubMed
68.
go back to reference Bennett S, Hoffman N, Monga M. Ephedrine-and guaifenesin-induced nephrolithiasis. J Altern Complement Med. 2004;10(6):967–9.PubMedCrossRef Bennett S, Hoffman N, Monga M. Ephedrine-and guaifenesin-induced nephrolithiasis. J Altern Complement Med. 2004;10(6):967–9.PubMedCrossRef
69.
go back to reference MMWR. Adverse events associated with ephedrine-containing products: Texas, December 1993–September 1995. JAMA. 1996;276(21):1711–2.CrossRef MMWR. Adverse events associated with ephedrine-containing products: Texas, December 1993–September 1995. JAMA. 1996;276(21):1711–2.CrossRef
70.
go back to reference Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32(1):153–9.PubMedCrossRef Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32(1):153–9.PubMedCrossRef
71.
go back to reference Pickens CL, Milliron AR, Fussner AL, Dversdall BC, Langenstroer P, Ferguson S, et al. Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, results in urolithiasis. Urology. 1999;54(1):23–7.PubMedCrossRef Pickens CL, Milliron AR, Fussner AL, Dversdall BC, Langenstroer P, Ferguson S, et al. Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, results in urolithiasis. Urology. 1999;54(1):23–7.PubMedCrossRef
72.
go back to reference Assimos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. Guaifenesin-and ephedrine-induced stones. J Endourol. 1999;13(9):665–7.PubMedCrossRef Assimos DG, Langenstroer P, Leinbach RF, Mandel NS, Stern JM, Holmes RP. Guaifenesin-and ephedrine-induced stones. J Endourol. 1999;13(9):665–7.PubMedCrossRef
73.
go back to reference Herman JR, Goldberg AS. New type of urinary calculus caused by antacid therapy. JAMA. 1960;174:1206–7.PubMed Herman JR, Goldberg AS. New type of urinary calculus caused by antacid therapy. JAMA. 1960;174:1206–7.PubMed
74.
go back to reference Lagergren C. Development of silica calculi after oral administration of magnesium trisilicate. J Urol. 1962;87:994–6.PubMed Lagergren C. Development of silica calculi after oral administration of magnesium trisilicate. J Urol. 1962;87:994–6.PubMed
75.
go back to reference Dalal RP, Goldfarb DS. Melamine-related kidney stones, renal toxicity. Nat Rev Nephrol. 2011;7(5):267–74.PubMedCrossRef Dalal RP, Goldfarb DS. Melamine-related kidney stones, renal toxicity. Nat Rev Nephrol. 2011;7(5):267–74.PubMedCrossRef
76.
go back to reference Burns K. Events leading to the major recall of pet foods. J Am Vet Med Assoc. 2007;230(11):1600–2.PubMedCrossRef Burns K. Events leading to the major recall of pet foods. J Am Vet Med Assoc. 2007;230(11):1600–2.PubMedCrossRef
77.
go back to reference Chen JS. A worldwide food safety concern in 2008: melamine-contaminated infant formula in China caused urinary tract stone in 290, 000 children in China. Chin Med J (Engl). 2009;122(3):243–4.CrossRef Chen JS. A worldwide food safety concern in 2008: melamine-contaminated infant formula in China caused urinary tract stone in 290, 000 children in China. Chin Med J (Engl). 2009;122(3):243–4.CrossRef
78.
go back to reference Guan N, Fan Q, Ding J, Zhao Y, Lu J, Ai Y, et al. Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med. 2009;360(11):1067–74.PubMedCrossRef Guan N, Fan Q, Ding J, Zhao Y, Lu J, Ai Y, et al. Melamine-contaminated powdered formula and urolithiasis in young children. N Engl J Med. 2009;360(11):1067–74.PubMedCrossRef
79.
go back to reference Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE. Topiramate-induced nephrolithiasis. J Endourol. 2002;16(4):229–31.PubMedCrossRef Kuo RL, Moran ME, Kim DH, Abrahams HM, White MD, Lingeman JE. Topiramate-induced nephrolithiasis. J Endourol. 2002;16(4):229–31.PubMedCrossRef
80.
go back to reference Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006;48(4):555–63.PubMedCrossRef Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006;48(4):555–63.PubMedCrossRef
81.
go back to reference Herring LC. Observations on the analysis of ten thousand urinary calculi. J Urol. 1962;88(4):545–62.PubMed Herring LC. Observations on the analysis of ten thousand urinary calculi. J Urol. 1962;88(4):545–62.PubMed
82.
go back to reference Kohri K, Takada M, Kambara N, Kurita T. Ammonium urate urinary stone: its surface structure and incidence in Japan. Int Urol Nephrol. 1989;21(3):275–9.PubMedCrossRef Kohri K, Takada M, Kambara N, Kurita T. Ammonium urate urinary stone: its surface structure and incidence in Japan. Int Urol Nephrol. 1989;21(3):275–9.PubMedCrossRef
83.
go back to reference Soble JJ, Hamilton BD, Streem SB. Ammonium acid urate calculi: a reevaluation of risk factors. J Urol. 1999;161(3):869–73.PubMedCrossRef Soble JJ, Hamilton BD, Streem SB. Ammonium acid urate calculi: a reevaluation of risk factors. J Urol. 1999;161(3):869–73.PubMedCrossRef
84.
go back to reference Pichette V, Bonnardeaux A, Cardinal J, Houde M, Nolin L, Boucher A, et al. Ammonium acid urate crystal formation in adult North American stone-formers. Am J Kidney Dis. 1997;30(2):237–42.PubMedCrossRef Pichette V, Bonnardeaux A, Cardinal J, Houde M, Nolin L, Boucher A, et al. Ammonium acid urate crystal formation in adult North American stone-formers. Am J Kidney Dis. 1997;30(2):237–42.PubMedCrossRef
86.
go back to reference Dick WH, Lingeman JE, Preminger GM, Smith LH, Wilson DM, Shirrell WL. Laxative abuse as a cause for ammonium urate renal calculi. J Urol. 1990;143(2):244–7.PubMed Dick WH, Lingeman JE, Preminger GM, Smith LH, Wilson DM, Shirrell WL. Laxative abuse as a cause for ammonium urate renal calculi. J Urol. 1990;143(2):244–7.PubMed
87.
go back to reference Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, et al. Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc. 1993;7(1):371–9.PubMed Caudarella R, Rizzoli E, Pironi L, Malavolta N, Martelli G, Poggioli G, et al. Renal stone formation in patients with inflammatory bowel disease. Scanning Microsc. 1993;7(1):371–9.PubMed
88.
89.
go back to reference Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55(5):401–12.PubMedCrossRef Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine. 1976;55(5):401–12.PubMedCrossRef
90.
go back to reference Kennedy HJ, Fletcher EW, Truelove SC. Urinary stones in subjects with a permanent ileostomy. Br J Surg. 1982;69(11):661–4.PubMedCrossRef Kennedy HJ, Fletcher EW, Truelove SC. Urinary stones in subjects with a permanent ileostomy. Br J Surg. 1982;69(11):661–4.PubMedCrossRef
91.
go back to reference Bambach CP, Robertson WG, Peacock M, Hill GL. Effect of intestinal surgery on the risk of urinary stone formation. Gut. 1981;22(4):257–63.PubMedCrossRef Bambach CP, Robertson WG, Peacock M, Hill GL. Effect of intestinal surgery on the risk of urinary stone formation. Gut. 1981;22(4):257–63.PubMedCrossRef
92.
go back to reference Bowyer RC, McCulloch RK, Brockis JG, Ryan GD. Factors affecting the solubility of ammonium acid urate. Clin Chem Acta. 1979;95(1):17–22.CrossRef Bowyer RC, McCulloch RK, Brockis JG, Ryan GD. Factors affecting the solubility of ammonium acid urate. Clin Chem Acta. 1979;95(1):17–22.CrossRef
93.
go back to reference Boyce WH, King JS Jr. Crystal-matrix interrelations in calculi. J Urol. 1959;81(3):351–65.PubMed Boyce WH, King JS Jr. Crystal-matrix interrelations in calculi. J Urol. 1959;81(3):351–65.PubMed
94.
go back to reference Boyce WH, Garvey FK. The amount and nature of the organic matrix in urinary calculi: a review. J Urol. 1956;76(3):213–27.PubMed Boyce WH, Garvey FK. The amount and nature of the organic matrix in urinary calculi: a review. J Urol. 1956;76(3):213–27.PubMed
95.
go back to reference Stoller ML, Gupta M, Bolton D, Irby PB 3rd. Clinical correlates of the gross, radiographic, and histologic features of urinary matrix calculi. J Endourol. 1994;8(5):335–40.PubMedCrossRef Stoller ML, Gupta M, Bolton D, Irby PB 3rd. Clinical correlates of the gross, radiographic, and histologic features of urinary matrix calculi. J Endourol. 1994;8(5):335–40.PubMedCrossRef
96.
go back to reference Bommer J, Ritz E, Tschöpe W, Waldherr R, Gebhardt M. Urinary matrix calculi consisting of microfibrillar protein in patients on maintenance hemodialysis. Kidney Int. 1979;16(6):722–8.PubMedCrossRef Bommer J, Ritz E, Tschöpe W, Waldherr R, Gebhardt M. Urinary matrix calculi consisting of microfibrillar protein in patients on maintenance hemodialysis. Kidney Int. 1979;16(6):722–8.PubMedCrossRef
97.
go back to reference Shah HN, Kharodawala S, Sodha HS, Khandkar AA, Hegde SS, Bansal MB. The management of renal matrix calculi: a single-centre experience over 5 years. BJU Int. 2009;103(6):810–4.PubMedCrossRef Shah HN, Kharodawala S, Sodha HS, Khandkar AA, Hegde SS, Bansal MB. The management of renal matrix calculi: a single-centre experience over 5 years. BJU Int. 2009;103(6):810–4.PubMedCrossRef
98.
go back to reference Bani-Hani AH, Segura JW, Leroy AJ. Urinary matrix calculi: our experience at a single institution. J Urol. 2005;173(1):120–3.PubMedCrossRef Bani-Hani AH, Segura JW, Leroy AJ. Urinary matrix calculi: our experience at a single institution. J Urol. 2005;173(1):120–3.PubMedCrossRef
Metadata
Title
Miscellaneous Stone Types
Authors
James B. Cutrell
Robert F. Reilly
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Clinical & Translational Metabolism / Issue 3-4/2011
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-011-9099-1

Other articles of this Issue 3-4/2011

Clinical Reviews in Bone and Mineral Metabolism 3-4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine